Zobrazeno 31 - 40
of 191
pro vyhledávání: ''
Autor:
Chen Jiang, Alan P. Venook, Alexander B. Sibley, Ivo D. Shterev, Kouros Owzar, Herbert Hurwitz, Stephanie M. Cushman, Andrew B. Nixon, Donna Niedzwiecki, Ace J. Hatch
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research, vol 21, iss 5
Purpose: Formalin-fixed, paraffin-embedded tumor samples from CALGB 80203 were analyzed for expression of EGFR axis–related genes to identify prognostic or predictive biomarkers for cetuximab treatment. Patients and Methods: Patients (238 total) wi
Autor:
Beth O. Van Emburgh, Sebastijan Hobor, Federica Di Nicolantonio, Alberto Bardelli, Sandra Misale, Emily Crowley
Publikováno v:
Clinical Cancer Research. 20:6429-6438
Purpose: Targeted inhibition of EGFR with the mAbs cetuximab or panitumumab is a valuable treatment for RAS wild-type colorectal cancers. The efficacy of EGFR blockade is limited by the emergence of acquired resistance often attributed to secondary K
Publikováno v:
Cancer Epidemiology, Biomarkers & Prevention. 24:1416-1418
In metastatic colorectal cancer, KRAS and NRAS genotyping is mandatory before prescription of panitumumab or cetuximab. In order to perform such molecular tests, the French National Cancer Institute has set up a nationwide network of molecular center
Autor:
Somy Yoon, Sung Pil Hong, Ik Joo Chung, So Yeon Park, Jun Eul Hwang, Jeong A Bae, Kyung Keun Kim, Jae Hyuk Lee, Yoon Jin Cha, Hoguen Kim, Hangun Kim, Young Woo Seo
Publikováno v:
Clinical Cancer Research. 20:4115-4128
Purpose: EGF-stimulated signaling via EGF receptor (EGFR) is important in colorectal tumorigenesis and drug targeting. However, anti-EGFR therapy is not effective in a subset of patients with colorectal cancer, suggesting that unidentified EGF-stimul
Autor:
Qian Shi, Suresh G. Nair Md, Garth D. Nelson, David Tougeron, Frank A. Sinicrope, Steven R. Alberts, Michelle R. Mahoney, Richard M. Goldberg, Stephen N. Thibodeau, Daniel J. Sargent, Harry H. Yoon
Publikováno v:
Clinical Cancer Research. 20:3033-3043
Purpose: We examined the prognostic impact of specific KRAS mutations in patients with stage III colon adenocarcinoma receiving adjuvant FOLFOX alone or combined with cetuximab in a phase III trial (N0147). Analysis was restricted to BRAF–wild-type
Autor:
Stephen H. Friend, Brian Dougherty, Robert McEwen, Gilles Manceau, Pierre Laurent-Puig, Justin Guinney, Jonathan R. Dry, Erich Huang, Jean-Charles Soria, Michel Ducreux, Kai-Ming Chang, Jonathan M. J. Derry, KJ Kao, Charles Ferté, Kevin Hudson, Claus Bendtsen
Publikováno v:
Clinical Cancer Research. 20:265-272
Purpose: KRAS wild-type status is an imperfect predictor of sensitivity to anti-EGF receptor (EGFR) monoclonal antibodies in colorectal cancer, motivating efforts to identify novel molecular aberrations driving RAS. This study aimed to build a quanti
Autor:
Sang-Hyun Song, Young-Won Cho, Sae-Won Han, Dong Wook Min, Hwang-Phill Kim, Yoojoo Lim, Tae-You Kim
Publikováno v:
Cancer Research. 79:36-36
Organoids are known to best in vitro model system which mostly mimic genetic, phenotypic feature of its origin. And it is expected and suitable to variable disease modeling and study. For cancer modeling using organoids as co-clinical model, our grou
Autor:
Elizabeth Garrett-Mayer, Julie Gottlieb Fisher, Timothy L. Cannon, Pam K. Mangat, Ricardo H. Alvarez, Samiha Islam, Susan Halabi, Andrew L. Rygiel, Kaitlyn R. Antonelli, Theodore Pollock, Suanna S. Bruinooge, Richard L. Schilsky, Jared Addison Cotta, Pamela A. Crilley, Tareq Al Baghdadi
Publikováno v:
Cancer Research. 79:CT135-CT135
Background: The TAPUR Study is a phase II multi-basket study that evaluates the anti-tumor activity of commercially available targeted agents in pts with advanced cancers with genomic alterations known to be drug targets. Results in two cohorts of BC
Autor:
I. van Praagh, Catherine Abrial, Frédérique Penault-Llorca, Anne Cayre, Y-J Bignon, Nina Radosevic-Robin, Yannick Bidet, J.P. Jacquin, J-M Nabholtz, F Kwiatkoswki, A-V Bourcier, P. Chollet, N. Chalabi, F Del Piano, M.M. Dauplat, B. Nayl, V. Servent, Pascale Dubray-Longeras, M-A Mouret-Reynier, Nancy Uhrhammer
Publikováno v:
Cancer Research. 73:P1-08
Background: TNBC is a heterogenous group of tumors for some of which the Epithelial Growth Factor Receptor pathway (EGFR) may play an important role. We evaluated the efficacy and toxicity of an anti-EGFR antibody (cetuximab) combined with docetaxel,
Autor:
Ekkehard Moessner, Pablo Umana, Sylvia Herter, Christian Gerdes, Birgit Bossenmaier, Carola Ries, Michaela Roemmele, Nicolini Valeria G, Hans Joachim Mueller, Thomas Friess, Olivier Freytag, Erwin van Puijenbroek, Sabine Lang
Publikováno v:
Clinical Cancer Research. 19:1126-1138
Purpose: Anti-EGF receptor (EGFR) antibodies and small-molecule tyrosine kinase inhibitors have shown activity in epithelial tumors; however, agents that work by blocking the EGFR growth signal are ineffective when the oncogenic stimulus arises downs